May 23, 2024 07:12 AM EDT

AstraZeneca taps more China-derived tech with $19M cancer deal for Nona antibodies

Ayisha Sharma

News Reporter

AstraZeneca on Thursday inked a license and option deal with the US offshoot of a Chinese-Dutch company, with an eye to creating antibody-based targeted cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca taps more China-derived tech with $19M cancer deal for Nona antibodies

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

Rare pediatric disease vouchers face uncertain future after September

Gilead cancer drug magrolimab showed worrying trends around death

AI drug discovery startup goes public in Hong Kong, nabbing $115M to build on pharma partnerships

Stephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan closes first $500M+ biotech fund

De-risking the patient journey in cell therapies: Six key considerations

As­traZeneca taps more Chi­na-de­rived tech with $19M can­cer deal for Nona an­ti­bod­ies

News Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

AstraZeneca taps more China-derived tech with $19M cancer deal for Nona antibodies